Needham Maintains Buy on Viridian Therapeutics, Lowers Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has maintained a 'Buy' rating on Viridian Therapeutics (NASDAQ:VRDN), but lowered the price target from $40 to $30.
October 30, 2023 | 7:17 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Needham analyst has maintained a 'Buy' rating on Viridian Therapeutics but lowered the price target from $40 to $30.
The news is directly related to Viridian Therapeutics. The maintained 'Buy' rating indicates a positive outlook for the company, but the lowered price target may indicate a slower growth rate than previously expected. This could have a neutral impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100